{"version":"1.0","type":"link","title":"Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.","author_name":"Zhong H 외","author_url":"https://prs-insight.online/author/Zhong%20H","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/94709","thumbnail_width":1200,"thumbnail_height":630}